Mutations in BRCA1 and BRCA2 were first discovered in the mid-1990s in families with multiple cases of breast and ovarian cancer and remain the major cause of inherited susceptibility to these malignancies. At first, testing for mutations in these genes was limited to women with cancer diagnosis at a young age or with a substantial family history, bilateral breast cancer, or both breast and ovarian cancer. Mounting evidence that BRCA1 and BRCA2 mutations account for a substantial proportion of breast and ovarian cancer, combined with emerging therapies based on BRCA1 or BRCA2 genotype, led to expansion of referral criteria to include many women with breast or ovarian cancer upon diagnosis. Read more…
Excited for tomorrow's BRCA panel at Limmud at 12:10. A chance to hear personal testimonies and think through the issues together #limmud
About 7 years ago from brca alliance's Twitter via Twitter for iPhone
@sapinker @dgmacarthur is the rise of professional ethicists not a symptom of the systemic failure of working scientists to address ethics?
About 7 years ago from brca alliance's Twitter via Twitter for iPhone
Serial measurements of CA125 with ultrasound screening improves survival and reduces unnecessary surgery scienceblog.cancerresearchuk.…
About 7 years ago from brca alliance's Twitter via Twitter for iPhone
Big launch today of the new BRCA PROTECT Research Clinic at UCL. Watch and please share our launch video: youtu.be/nn85HUexGC0
About 7 years ago from brca alliance's Twitter via TweetDeck
Courageous Women Create Art Campaign Against Cancer buzzpedia.org/2015/10/20/cou…
About 7 years ago from brca alliance's Twitter via TweetDeck